Birdwatch Note
2024-11-14 12:39:24 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
人は不死身では無いので、不死薬でもなければ、全く無害な物でも多数に使用すれば必ず死者が出ます。例えば、日本では水摂取後7日以内に毎年百万以上が亡くなります。前後関係は必ずしも因果関係を示しません https://www.mhlw.go.jp/toukei/list/81-1a.html 著者は本当に社員かどうか不明です。 書籍名から少なくとも開発担当ではないことが明らかです。 前書きに非公開情報や企業の内部情報はないと明言されています https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 従来型もワクチンによる被害は皆無か極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#29 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1856837942553317424
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1857040635343093976
- noteId - 1857040635343093976
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1731587964269
- tweetId - 1856837942553317424
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 人は不死身では無いので、不死薬でもなければ、全く無害な物でも多数に使用すれば必ず死者が出ます。例えば、日本では水摂取後7日以内に毎年百万以上が亡くなります。前後関係は必ずしも因果関係を示しません https://www.mhlw.go.jp/toukei/list/81-1a.html 著者は本当に社員かどうか不明です。 書籍名から少なくとも開発担当ではないことが明らかです。 前書きに非公開情報や企業の内部情報はないと明言されています https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 従来型もワクチンによる被害は皆無か極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#29 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html
Note Ratings
| rated at | rated by | |
| 2024-11-14 18:54:07 -0600 | Rating Details | |
| 2024-11-14 18:53:58 -0600 | Rating Details | |
| 2024-11-14 18:28:45 -0600 | Rating Details | |
| 2024-11-14 18:24:05 -0600 | Rating Details | |
| 2024-11-14 17:56:30 -0600 | Rating Details | |
| 2024-11-14 17:49:02 -0600 | Rating Details | |
| 2024-11-14 17:44:22 -0600 | Rating Details | |
| 2024-11-14 17:44:07 -0600 | Rating Details | |
| 2024-11-14 17:37:36 -0600 | Rating Details | |
| 2024-11-14 16:37:07 -0600 | Rating Details | |
| 2024-11-14 16:32:12 -0600 | Rating Details | |
| 2024-11-14 16:27:32 -0600 | Rating Details | |
| 2024-11-14 15:59:09 -0600 | Rating Details | |
| 2024-11-14 15:01:55 -0600 | Rating Details | |
| 2024-11-14 14:08:28 -0600 | Rating Details | |
| 2024-11-14 13:49:02 -0600 | Rating Details | |
| 2024-11-14 12:05:07 -0600 | Rating Details | |
| 2024-11-14 10:21:08 -0600 | Rating Details | |
| 2024-11-14 10:14:01 -0600 | Rating Details | |
| 2024-11-14 07:02:00 -0600 | Rating Details | |
| 2024-11-15 04:07:27 -0600 | Rating Details | |
| 2024-11-15 00:13:27 -0600 | Rating Details | |
| 2024-11-14 23:36:11 -0600 | Rating Details | |
| 2024-11-14 22:24:31 -0600 | Rating Details | |
| 2024-11-14 21:00:21 -0600 | Rating Details | |
| 2024-11-14 20:59:08 -0600 | Rating Details | |
| 2024-11-14 20:41:27 -0600 | Rating Details | |
| 2024-11-14 20:32:20 -0600 | Rating Details | |
| 2024-11-15 06:49:52 -0600 | Rating Details | |
| 2024-11-14 16:01:16 -0600 | Rating Details | |
| 2024-11-14 16:01:11 -0600 | Rating Details | |
| 2024-11-14 07:10:52 -0600 | Rating Details | |
| 2024-11-15 21:46:22 -0600 | Rating Details | |
| 2024-11-14 23:17:24 -0600 | Rating Details | |
| 2024-11-14 22:45:46 -0600 | Rating Details | |
| 2024-11-14 20:25:38 -0600 | Rating Details | |
| 2024-11-14 17:47:27 -0600 | Rating Details | |
| 2024-11-14 15:50:21 -0600 | Rating Details | |
| 2024-11-14 09:24:32 -0600 | Rating Details | |
| 2024-12-19 04:29:47 -0600 | Rating Details | |
| 2024-12-19 00:59:03 -0600 | Rating Details | |
| 2024-12-19 00:59:35 -0600 | Rating Details |